Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NORETHINDRONE

2 general benefit · 1 not a benefit

Other products in the same Health Canada class (G03A, G03AC) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit
  • Medroxyprogesterone (Depo-Provera): general benefit, Not a benefit, Listing status unconfirmed
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit

2 more in the class list below

Jencycla · DIN 02441306 · 0.35mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jencycla · DIN 02441306 Manufacturer: Lupin Pharma Canada Limited; listing date 2016-05-31 Health Canada: Marketed since 2018-08-14 · brand JENCYCLA · ATC G03AC01 NORETHISTERONE · form Tablet · route Oral · ingredients NORETHINDRONE 0.35 MG · company Lupin pharma canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Jencycla: Formulary list price $10.9900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.9900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92570 · Verify on the e-Formulary ↗ (DIN 02441306)

Source record
DIN 02441306: Jencycla Raw flags: sec3=Y Item: 683200031; group id 802; item number 1963; lccId None; manufacturer id LUP Source form: Tab-28 Pk; strength: 0.35mg Recorded listing: General benefit Source prices (unrounded): $10.9900; ministry $10.9900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441306 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92570
Interchangeable products
Micronor · DIN 00037605 · not recorded Movisse · DIN 02410303 · $10.9900
Shortage status: resolved shortage (ended 2020-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02441306
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Movisse · DIN 02410303 · 0.35mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Movisse · DIN 02410303 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2016-03-30 Health Canada: Marketed since 2026-07-10 · brand MOVISSE · ATC G03AC01 NORETHISTERONE · form Tablet · route Oral · ingredients NORETHINDRONE 0.35 MG · company Senador laboratories private limited · schedule Prescription
Check this DIN again · Health Canada product record

Movisse: Formulary list price $10.9900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.9900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89495 · Verify on the e-Formulary ↗ (DIN 02410303)

Source record
DIN 02410303: Movisse Raw flags: sec3=Y Item: 683200031; group id 802; item number 1963; lccId None; manufacturer id MYL Source form: Tab-28 Pk; strength: 0.35mg Recorded listing: General benefit Source prices (unrounded): $10.9900; ministry $10.9900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02410303 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89495
Interchangeable products
Jencycla · DIN 02441306 · $10.9900 Micronor · DIN 00037605 · not recorded
Shortage status: resolved shortage (ended 2022-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02410303
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Micronor · DIN 00037605 · 0.35mg · tablets, 28-pack

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-09 — choose a marketed DIN from the same-category list.Discontinued 2020-07-09 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-09 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Micronor · DIN 00037605 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-07-09 · brand MICRONOR TABLETS 28-DAY · ATC G03AC01 NORETHISTERONE · form Tablet · route Oral · ingredients NORETHINDRONE 0.35 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Micronor: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1290 · Verify on the e-Formulary ↗ (DIN 00037605)

Source record
DIN 00037605: Micronor Raw flags: notABenefit=Y, sec3=Y Item: 683200031; group id 802; item number 1963; lccId None; manufacturer id JAN Source form: Tab-28 Pk; strength: 0.35mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00037605 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1290
Interchangeable products
Jencycla · DIN 02441306 · $10.9900 Movisse · DIN 02410303 · $10.9900
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00037605
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-07-09 — choose a marketed DIN from the same-category list.

ETHINYL ESTRADIOL & NORETHINDRONE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G03A, G03AC) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit
  • Medroxyprogesterone (Depo-Provera): general benefit, Not a benefit, Listing status unconfirmed
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit

2 more in the class list below

Brevicon · DIN 02187086 · 0.035mg & 0.5mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Brevicon · DIN 02187086 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand BREVICON 0.5/35 TABLETS (21-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 0.5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Brevicon: Formulary list price $16.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20162 · Verify on the e-Formulary ↗ (DIN 02187086)

Source record
DIN 02187086: Brevicon Raw flags: sec3=Y Item: 683200049; group id 798; item number 1946; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 0.035mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02187086 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20162
Shortage status: active shortage (reported 2026-03-17, estimated to end 2027-03-19, last updated 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187086
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brevicon 1/35 · DIN 02189054 · 0.035mg & 1mg · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Brevicon 1/35 · DIN 02189054 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand BREVICON 1/35 TABLETS (21-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 1 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Brevicon 1/35: Formulary list price $16.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42921 · Verify on the e-Formulary ↗ (DIN 02189054)

Source record
DIN 02189054: Brevicon 1/35 Raw flags: sec3=Y Item: 683200053; group id 798; item number 1947; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 0.035mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02189054 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42921
Shortage status: active shortage (reported not recorded, estimated to end 2027-03-19, last updated 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189054
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brevicon · DIN 02187094 · 0.035mg & 0.5mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Brevicon · DIN 02187094 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-04-18 · brand BREVICON 0.5/35 TABLETS (28-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL .035 MG, NORETHINDRONE .5 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Brevicon: Formulary list price $16.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42888 · Verify on the e-Formulary ↗ (DIN 02187094)

Source record
DIN 02187094: Brevicon Raw flags: sec3=Y Item: 683200050; group id 798; item number 1949; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 0.035mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02187094 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42888
Shortage status: active shortage (reported 2025-06-06, estimated to end 2027-03-19, last updated 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187094
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brevicon 1/35 · DIN 02189062 · 0.035mg & 1mg · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Brevicon 1/35 · DIN 02189062 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand BREVICON 1/35 TABLETS (28-DAY PACK) · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 1 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Brevicon 1/35: Formulary list price $16.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42922 · Verify on the e-Formulary ↗ (DIN 02189062)

Source record
DIN 02189062: Brevicon 1/35 Raw flags: sec3=Y Item: 683200054; group id 798; item number 1950; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 0.035mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.4500; ministry $16.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02189062 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42922
Shortage status: active shortage (reported 2026-01-02, estimated to end 2027-03-19, last updated 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189062
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synphasic · DIN 02187108 · 3 Phase · tablets, 21-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Synphasic · DIN 02187108 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2009-02-03 · brand SYNPHASIC 21 TABLETS · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 0.5 MG, NORETHINDRONE 1.0 MG, ETHINYL ESTRADIOL 0.035 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Synphasic: Formulary list price $13.6400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $13.6400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42889 · Verify on the e-Formulary ↗ (DIN 02187108)

Source record
DIN 02187108: Synphasic Raw flags: sec3=Y Item: 683200059; group id 798; item number 1948; lccId None; manufacturer id PFI Source form: Tab-21 Pk; strength: 3 Phase Recorded listing: General benefit Source prices (unrounded): $13.6400; ministry $13.6400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02187108 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42889
Shortage status: discontinued (2026-03-23, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187108
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Synphasic · DIN 02187116 · 3 Phase · tablets, 28-pack

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Synphasic · DIN 02187116 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2006-07-20 · brand SYNPHASIC 28 TABLETS · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE 0.5 MG, ETHINYL ESTRADIOL 0.035 MG, NORETHINDRONE 1.0 MG, ETHINYL ESTRADIOL 0.035 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Synphasic: Formulary list price $13.6400/unit (unit not stated in source; not the patient's cost)

Ministry pays: $13.6400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42890 · Verify on the e-Formulary ↗ (DIN 02187116)

Source record
DIN 02187116: Synphasic Raw flags: sec3=Y Item: 683200060; group id 798; item number 1951; lccId None; manufacturer id PFI Source form: Tab-28 Pk; strength: 3 Phase Recorded listing: General benefit Source prices (unrounded): $13.6400; ministry $13.6400 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02187116 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=42890
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187116
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ETHINYL ESTRADIOL & NORETHINDRONE ACETATE

All products: general benefit

Other products in the same Health Canada class (G03A, G03AC) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit
  • Medroxyprogesterone (Depo-Provera): general benefit, Not a benefit, Listing status unconfirmed
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit

2 more in the class list below

Minestrin 1/20 · DIN 00315966 · 0.02mg & 1mg · tablets, 21-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.Discontinued 2022-04-26 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Minestrin 1/20 · DIN 00315966 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-04-26 · brand MINESTRIN 1/20 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 20 MCG, NORETHINDRONE ACETATE 1 MG · company Allergan inc · schedule Prescription
Check this DIN again · Health Canada product record

Minestrin 1/20: Formulary list price $16.9915/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2255 · Verify on the e-Formulary ↗ (DIN 00315966)

Source record
DIN 00315966: Minestrin 1/20 Raw flags: sec3=Y Item: 683200045; group id 799; item number 1952; lccId None; manufacturer id WAR Source form: Tab-21 Pk; strength: 0.02mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00315966 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2255
Shortage status: resolved shortage (ended 2021-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00315966
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.

Minestrin 1/20 · DIN 00343838 · 0.02mg & 1mg · tablets, 28-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.Discontinued 2022-04-26 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Minestrin 1/20 · DIN 00343838 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-04-26 · brand MINESTRIN 1/20 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 20 MCG · company Allergan inc · schedule Prescription
Check this DIN again · Health Canada product record

Minestrin 1/20: Formulary list price $16.9915/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2254 · Verify on the e-Formulary ↗ (DIN 00343838)

Source record
DIN 00343838: Minestrin 1/20 Raw flags: sec3=Y Item: 683200046; group id 799; item number 1954; lccId None; manufacturer id WAR Source form: Tab-28 Pk; strength: 0.02mg & 1mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00343838 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2254
Shortage status: resolved shortage (ended 2021-02-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00343838
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-04-26 — choose a marketed DIN from the same-category list.

Loestrin 1.5/30 · DIN 00297143 · 0.03mg & 1.5mg · tablets, 21-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.Discontinued 2022-04-22 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Loestrin 1.5/30 · DIN 00297143 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-04-22 · brand LOESTRIN 1.5/30 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 30 MCG, NORETHINDRONE ACETATE 1.5 MG · company Allergan inc · schedule Prescription
Check this DIN again · Health Canada product record

Loestrin 1.5/30: Formulary list price $16.9915/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1922 · Verify on the e-Formulary ↗ (DIN 00297143)

Source record
DIN 00297143: Loestrin 1.5/30 Raw flags: sec3=Y Item: 683200006; group id 799; item number 1953; lccId None; manufacturer id WAR Source form: Tab-21 Pk; strength: 0.03mg & 1.5mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00297143 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1922
Shortage status: resolved shortage (ended 2021-01-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00297143
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-04-22 — choose a marketed DIN from the same-category list.

Loestrin 1.5/30 · DIN 00353027 · 0.03mg & 1.5mg · tablets, 28-pack

General benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.Discontinued 2022-01-20 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Loestrin 1.5/30 · DIN 00353027 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-01-20 · brand LOESTRIN 1.5/30 · ATC G03AA05 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 30 MCG, NORETHINDRONE ACETATE 1.5 MG · company Allergan inc · schedule Prescription
Check this DIN again · Health Canada product record

Loestrin 1.5/30: Formulary list price $16.9915/unit (unit not stated in source; not the patient's cost)

Ministry pays: $16.9915 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2386 · Verify on the e-Formulary ↗ (DIN 00353027)

Source record
DIN 00353027: Loestrin 1.5/30 Raw flags: sec3=Y Item: 683200048; group id 799; item number 1955; lccId None; manufacturer id WAR Source form: Tab-28 Pk; strength: 0.03mg & 1.5mg Recorded listing: General benefit Source prices (unrounded): $16.9915; ministry $16.9915 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00353027 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2386
Shortage status: discontinued (2021-06-25, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00353027
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-01-20 — choose a marketed DIN from the same-category list.

NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G03A, G03AC) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit
  • Medroxyprogesterone (Depo-Provera): general benefit, Not a benefit, Listing status unconfirmed
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit

2 more in the class list below

Elfy · DIN 02553481 · 1mg/10mcg & 10mcg · tablet-28 tablet Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Elfy · DIN 02553481 Manufacturer: Apotex Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-04-20 · brand ELFY · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients ETHINYL ESTRADIOL 10 MCG, ETHINYL ESTRADIOL 10 MCG, NORETHINDRONE ACETATE 1 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104242 · Verify on the e-Formulary ↗ (DIN 02553481)

Source record
DIN 02553481: Elfy Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 681200006; group id 730; item number 1794; lccId None; manufacturer id APX Source form: Tab-28 Tab Pk; strength: 1mg/10mcg & 10mcg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $16.1084; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553481 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104242
Interchangeable products
Lolo · DIN 02417456 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553481
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lolo · DIN 02417456 · 1mg/10mcg & 10mcg · tablet-28 tablet Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Lolo (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Lolo · DIN 02417456 Manufacturer: AbbVie Corporation; listing date 2026-06-30 Health Canada: Marketed since 2024-05-06 · brand LOLO · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 10 MCG, ETHINYL ESTRADIOL 10 MCG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lolo: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90215 · Verify on the e-Formulary ↗ (DIN 02417456)

Source record
DIN 02417456: Lolo Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 681200006; group id 730; item number 1794; lccId None; manufacturer id ABV Source form: Tab-28 Tab Pk; strength: 1mg/10mcg & 10mcg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417456 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90215
Interchangeable products
Elfy · DIN 02553481 · not recorded
Shortage status: resolved shortage (ended 2019-09-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02417456
Shortage record checked 2026-09-13T08:10:21.292534+00:00

RELUGOLIX & ESTRADIOL & NORETHINDRONE ACETATE

All products: general benefit

Other products in the same Health Canada class (G03A, G03AC) — coverage varies; not interchangeable

  • Drospirenone (Slynd): general benefit
  • Etonogestrel (Nexplanon): general benefit
  • Medroxyprogesterone (Depo-Provera): general benefit, Not a benefit, Listing status unconfirmed
  • Desogestrel + ethinyl estradiol (Marvelon 21): general benefit
  • Drospirenone + ethinyl estradiol (Yasmin 21): general benefit
  • Ethinyl estradiol + levonorgestrel (Alesse 21): general benefit, Not a benefit

2 more in the class list below

Myfembree · DIN 02541742 · 40mg & 1mg & 0.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Myfembree · DIN 02541742 Manufacturer: Knight Therapeutics Inc.; listing date 2026-01-30 Health Canada: Marketed since 2025-10-28 · brand MYFEMBREE · ATC H01CC54 RELUGOLIX, ESTRADIOL AND NORETHISTERONE · form Tablet · route Oral · ingredients RELUGOLIX 40 MG, ESTRADIOL 1 MG, NORETHINDRONE ACETATE 0.5 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Myfembree: Formulary list price $9.3150/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.3150 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103029 · Verify on the e-Formulary ↗ (DIN 02541742)

Source record
DIN 02541742: Myfembree Raw flags: sec3=Y Item: 681800021; group id 738; item number 1806; lccId None; manufacturer id KNT Source form: Tab; strength: 40mg & 1mg & 0.5mg Recorded listing: General benefit Source prices (unrounded): $9.3150; ministry $9.3150 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541742 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103029
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541742
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (68:00 HORMONES AND SUBSTITUTES) and how they are covered

Matched class: 68:00 HORMONES AND SUBSTITUTES

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CANAGLIFLOZIN, CICLESONIDE, DANAZOL, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE, ESTRADIOL HEMIHYDRATE & PROGESTERONE, ETONOGESTREL, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, INSULIN (30% NEUTRAL & 70% ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC, INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN), INSULIN ASPART 30% & INSULIN ASPART PROTAMINE 70%, INSULIN DEGLUDEC, INSULIN DETEMIR, INSULIN GLARGINE & LIXISENATIDE, INSULIN GLULISINE (DNA ORIGIN), INSULIN HUMAN BIOSYNTHETIC, INSULIN HUMAN BIOSYNTHETIC 30% & ISOPHANE 70%, INSULIN INJECTION, HUMAN BIOSYNTHETIC, INSULIN LISPRO & INSULIN LISPRO PROTAMINE, LEVONORGESTREL, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, PROPYLTHIOURACIL, RELUGOLIX, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN, THYROTROPIN ALFA, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, CALCITONIN (SALMON SYNTHETIC), CONJUGATED ESTROGENS, DESMOPRESSIN ACETATE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, ESTRADIOL, ETHINYL ESTRADIOL & LEVONORGESTREL, GLICLAZIDE, GLYBURIDE, HYDROCORTISONE, INSULIN ASPART, INSULIN GLARGINE, INSULIN LISPRO, LEVOTHYROXINE (SODIUM), MEDROXYPROGESTERONE ACETATE, METFORMIN HCL, METHIMAZOLE, NORGESTIMATE & ETHINYL ESTRADIOL, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:00 HORMONES AND SUBSTITUTES

RELUGOLIX

· 1 products · General benefit · strengths: 120mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:00 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

FLUTICASONE FUROATE

· 2 products · General benefit · strengths: 100mcg, 200mcg · Blister Pd Inh-30 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 74 more
Full class listing Related classes:

Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL, LEVONORGESTREL 68:12 Contraceptives

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

LEVONORGESTREL

· 2 products · General benefit · strengths: 19.5mg, 52mg · Insert

ETHINYL ESTRADIOL & ETONOGESTREL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.120mg & 0.015mg/24 hr · Slow Release Vag Ring Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids

Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered

Matched class: 68:32 Progestogens and Oral Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, LEVONORGESTREL Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, MEDROXYPROGESTERONE ACETATE, NORGESTIMATE & ETHINYL ESTRADIOL 68:32 Progestogens and Oral Contraceptives

DROSPIRENONE

· 1 products · General benefit · strengths: 4mg · Tab-28 Tab Pk

MEDROXYPROGESTERONE ACETATE

· 10 products · Temporary benefit (2), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (4), Listed, not a benefit (1) · strengths: 150mg/mL, 2.5mg, 5mg, 10mg, 100mg · Inj Sol-1mL Pref Syr, Tab

DESOGESTREL & ETHINYL ESTRADIOL

· 12 products · General benefit · strengths: 0.15mg & 0.03mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tabs-21 Pk, Tabs-28 Pk

DROSPIRENONE & ETHINYL ESTRADIOL

· 9 products · General benefit · strengths: 3.0mg & 0.03mg, 3.0mg & 0.02mg · Tab-21 Pk, Tab-28 Pk

ETHINYL ESTRADIOL & LEVONORGESTREL

· 20 products · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 20mcg & 100mcg, 0.03mg & 0.15mg, 3 Phase · Tab-21 Pk, Tab-28 Pk, Tab-91 Pk

LEVONORGESTREL

· 4 products · General benefit · strengths: 1.5mg · Tab-1 Tab Pk

NORGESTIMATE & ETHINYL ESTRADIOL

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 3 Phase · Tab-21 Pk, Tab-28 Pk

DIENOGEST

· 5 products · Limited Use, codes 432 · strengths: 2mg · Tab

CYPROTERONE ACETATE & ETHINYL ESTRADIOL

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg & 0.035mg · Tab-21 Pk

PROGESTERONE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:32
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: conception control
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE & ETHINYL ESTRADIOL DESOGESTREL & ETHINYL ESTRADIOL · General benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077799.PDF; date NOV 20, 2024; DIN 02042479; fetched 2026-09-10 Product monograph DROSPIRENONE & ETHINYL ESTRADIOL · General benefit • Conception Control PM: https://pdf.hres.ca/dpd_pm/00080997.PDF; date 2025-07-07; DIN 02261723; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & ETONOGESTREL · Off-Formulary Interchangeable, not an ODB benefit • Conception control PM: https://pdf.hres.ca/dpd_pm/00077755.PDF; date DEC 12, 2004; DIN 02253186; fetched 2026-09-10 Product monograph ETHINYL ESTRADIOL & LEVONORGESTREL · General benefit (18), Off-Formulary Interchangeable, not an ODB benefit (2) 1 Indications TRIQUILAR (levonorgestrel and ethinyl estradiol) is indicated for: • Conception control 1.1 Pediatrics Pediatrics (˂16 years of age): Based on the data submitted and reviewed by Health Canada, Health Canada has authorized an indication in women of reproductive age. PM: https://pdf.hres.ca/dpd_pm/00081001.PDF; date 2025-07-07; DIN 00707503; fetched 2026-09-10 Product monograph NORGESTIMATE & ETHINYL ESTRADIOL · Listed, not a benefit (4), General benefit (6) Indications TRI-CIRA LOTM 21 and TRI-CIRA LOTM 28 (Norgestimate and Ethinyl Estradiol Tablets) are indicated for:  Conception control. 1.1. PM: https://pdf.hres.ca/dpd_pm/00081457.PDF; date 2025-08-21; DIN 02401967; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE MOVISSE Tablets are indicated for conception control. MOVISSE Tablets contain a low dosage of norethindrone without the addition of an estrogen agent. Progestin-only pills are often called "progestin-only pills" or the "mini-pill". https://pdf.hres.ca/dpd_pm/00085300.PDF PM date: JUL 10, 2026 Source product: MOVISSE; DIN 02410303; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: • the prevention of pregnancy. 1.1. Pediatrics The safety and efficacy of BREVICON has been established in women of reproductive age. Use of these products before menarche is not indicated. 1.2. Geriatrics BREVICON is not indicated for use in postmenopausal women. https://pdf.hres.ca/dpd_pm/00081309.PDF PM date: 2025-08-07 Source product: BREVICON 0.5/35 TABLETS (21-DAY PACK); DIN 02187086; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
1 INDICATIONS LOLO® (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) is indicated for: • the prevention of pregnancy. In a one year (thirteen 28-day cycles) multicenter open-label clinical trial 1,582 women were studied to assess the safety and efficacy of LOLO. In this study 1,270 women 18 to 35 years of age were studied to assess the efficacy of LOLO, completing the equivalent of 12,482 28-day evaluable cycles of exposure. The pregnancy rate (Pearl Index [PI]) in women 18 to 35 years of age was 2.92 pregnancies per 100 women-years of use. See 14 CLINICAL TRIALS. The efficacy of LOLO in women with a body mass index > 35 kg/m2 has not been evaluated. Exposure to exogenous estrogen with LOLO is less than with other combined oral contraceptives with similar synthetic estrogens. Any benefits from the lower estrogen exposure provided by LOLO have not been evaluated. 1.1 Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for… https://pdf.hres.ca/dpd_pm/00077458.PDF PM date: DEC 12, 2013 Source product: LOLO; DIN 02417456; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS MYFEMBREE (relugolix, estradiol, and norethindrone acetate tablets) is indicated in premenopausal women for the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis. 1.1 Pediatrics Pediatrics (<18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: MYFEMBREE is not indicated in postmenopausal women and has not been studied in women over 50 years of age. https://pdf.hres.ca/dpd_pm/00082196.PDF PM date: OCT 13, 2023 Source product: MYFEMBREE; DIN 02541742; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Micronor · DIN 00037605 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00037605

Check this DIN again

Brevicon · DIN 02187086 Shortage status: active shortage (reported 2026-03-17, estimated to end 2027-03-19, last updated 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187086

Check this DIN again

Brevicon 1/35 · DIN 02189054 Shortage status: active shortage (reported not recorded, estimated to end 2027-03-19, last updated 2026-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189054

Check this DIN again

Brevicon · DIN 02187094 Shortage status: active shortage (reported 2025-06-06, estimated to end 2027-03-19, last updated 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187094

Check this DIN again

Brevicon 1/35 · DIN 02189062 Shortage status: active shortage (reported 2026-01-02, estimated to end 2027-03-19, last updated 2026-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02189062

Check this DIN again

Synphasic · DIN 02187108 Shortage status: discontinued (2026-03-23, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187108

Check this DIN again

Synphasic · DIN 02187116 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02187116

Check this DIN again

Loestrin 1.5/30 · DIN 00353027 Shortage status: discontinued (2021-06-25, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00353027

Check this DIN again

Other review policies

For Micronor, Elfy, Lolo: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026